Enliven Therapeutics Reports Positive Data for ELVN-001 in CML Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Source: Newsfilter
- Clinical Trial Results: In the ENABLE clinical trial, ELVN-001 achieved a 67% overall major molecular response (MMR) rate by 24 weeks, demonstrating its efficacy in chronic myeloid leukemia (CML) patients, particularly in heavily pretreated individuals, indicating its potential as a new treatment option.
- Safety and Tolerability: Among 161 enrolled patients, ELVN-001 exhibited a favorable safety profile, with only 6% discontinuing treatment due to adverse events, and the majority of treatment-emergent adverse events were Grade 1 or 2, reflecting its high selectivity and tolerability.
- Successful FDA Alignment: The recent meeting with the FDA resulted in agreement on the 80 mg once daily dose as the recommended dose for the ENABLE-2 trial, which is expected to initiate in the second half of 2026, marking a significant advancement for ELVN-001 towards further clinical stages.
- Broad Market Potential: As a potentially best-in-class drug targeting the BCR::ABL1 gene fusion, ELVN-001 may provide new treatment options for CML patients, especially those who have not responded to existing therapies, presenting significant market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELVN
Wall Street analysts forecast ELVN stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.860
Low
35.00
Averages
40.67
High
48.00
Current: 44.860
Low
35.00
Averages
40.67
High
48.00
About ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully completed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000 share over-allotment option at a price of $37.50 per share, indicating strong market demand and providing substantial funding for the company.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be allocated towards the development of small molecule therapeutics, further advancing its clinical-stage projects.
- Strong Underwriter Lineup: The offering was managed by prominent financial institutions including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, enhancing market confidence in Enliven and laying a solid foundation for future capital market activities.
- Compliance and Transparency: The offering was conducted under a SEC registration statement, ensuring compliance and transparency, which bolsters investor trust in corporate governance and provides a solid legal framework for future financing activities.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully closed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000-share over-allotment option at a public price of $37.50 per share, indicating strong market demand for its small molecule therapeutics.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be utilized to support the company's clinical-stage biopharmaceutical development, enhancing its competitive position in the market.
- Strong Underwriting Team: The offering was managed by prominent financial institutions including Jefferies, Morgan Stanley, and Barclays, reflecting investor confidence in Enliven and its potential for future growth.
- Regulatory Compliance: The offering was conducted under an SEC registration statement, ensuring compliance and enhancing investor trust in the company's transparency and legality, which is beneficial for future capital market activities.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Enliven Therapeutics Announces Key Trial Alignment and Public Offering
- Trial Progress: Enliven Therapeutics announced that its experimental drug ELVN-001 demonstrated significant efficacy in chronic myeloid leukemia patients, with 48% of patients in the 80 mg daily dose group achieving a major molecular response, indicating strong potential for treatment success and likely boosting the company's future market performance.
- FDA Alignment: The company successfully aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial, expected to commence in the second half of 2026, marking a significant advancement in the company's clinical development efforts.
- Capital Raising Initiative: Enliven announced the pricing of its upsized public offering, expected to raise approximately $400 million in gross proceeds, which will provide essential funding for its research projects and further propel the development of ELVN-001.
- Analyst Ratings Optimistic: According to Koyfin data, all 10 analysts covering ELVN stock rate it as a 'Buy', with a 12-month price target of $60.11, representing a potential upside of about 49% from the last closing price, reflecting strong market confidence in the company's future performance.
See More
Enliven Therapeutics Upsizes Public Offering to $400 Million
- Offering Size Increase: Enliven Therapeutics has increased its public offering size from an initially announced $250 million to $400 million, indicating strong market demand for its shares and providing the company with ample funding to advance its research and development efforts.
- Stock Pricing: The offering consists of 8.93 million shares of common stock priced at $37.50 per share, and additionally, pre-funded warrants to purchase up to 1.73 million shares at $37.499 per warrant, enhancing investor participation and potentially elevating the company's market position in the biopharmaceutical sector.
- Transaction Completion Timeline: The transaction is expected to close around June 15, 2026, reflecting the company's active engagement in the capital markets and confidence in future growth, while ensuring funding for subsequent clinical trials and product development.
- Underwriter Option: Underwriters have been granted a 30-day option to purchase up to an additional 1.6 million shares of common stock at the public offering price, providing the company with flexibility for further financing, which may play a crucial role in responding to future market demand changes.
See More
Enliven Therapeutics Completes Upsized Public Offering
- Upsized Offering: Enliven Therapeutics has priced its upsized public offering of 8,933,334 shares at $37.50 per share, expecting gross proceeds of approximately $400 million, which reflects strong market demand for its small molecule therapeutics and enhances the company's financial capacity to support R&D initiatives.
- Pre-Funded Warrant Option: Investors have the option to purchase up to 1,733,333 shares via pre-funded warrants at $37.499 each, a flexible financing approach that not only attracts more investors but also provides additional funding sources to address future market challenges.
- Strong Underwriter Lineup: The offering is managed by prominent financial institutions including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, which demonstrates market confidence in Enliven and adds significant credibility to the company's reputation in capital markets.
- Compliance and Transparency: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which enhances investor trust and aids the company in attracting more investors to support its long-term growth strategy.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully completed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000 share over-allotment option at a price of $37.50 per share, indicating strong market demand and providing substantial funding for the company.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be allocated towards the development of small molecule therapeutics, further advancing its clinical-stage projects.
- Strong Underwriter Lineup: The offering was managed by prominent financial institutions including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, enhancing market confidence in Enliven and laying a solid foundation for future capital market activities.
- Compliance and Transparency: The offering was conducted under a SEC registration statement, ensuring compliance and transparency, which bolsters investor trust in corporate governance and provides a solid legal framework for future financing activities.
See More
Enliven Therapeutics Closes $460 Million Upsized Public Offering
- Upsized Offering: Enliven Therapeutics successfully closed an upsized public offering of 10,533,334 shares, including the full exercise of a 1,600,000-share over-allotment option at a public price of $37.50 per share, indicating strong market demand for its small molecule therapeutics.
- Significant Proceeds: The offering generated approximately $460 million in gross proceeds before deducting underwriting discounts and other expenses, which will be utilized to support the company's clinical-stage biopharmaceutical development, enhancing its competitive position in the market.
- Strong Underwriting Team: The offering was managed by prominent financial institutions including Jefferies, Morgan Stanley, and Barclays, reflecting investor confidence in Enliven and its potential for future growth.
- Regulatory Compliance: The offering was conducted under an SEC registration statement, ensuring compliance and enhancing investor trust in the company's transparency and legality, which is beneficial for future capital market activities.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Enliven Therapeutics Announces Key Trial Alignment and Public Offering
- Trial Progress: Enliven Therapeutics announced that its experimental drug ELVN-001 demonstrated significant efficacy in chronic myeloid leukemia patients, with 48% of patients in the 80 mg daily dose group achieving a major molecular response, indicating strong potential for treatment success and likely boosting the company's future market performance.
- FDA Alignment: The company successfully aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial, expected to commence in the second half of 2026, marking a significant advancement in the company's clinical development efforts.
- Capital Raising Initiative: Enliven announced the pricing of its upsized public offering, expected to raise approximately $400 million in gross proceeds, which will provide essential funding for its research projects and further propel the development of ELVN-001.
- Analyst Ratings Optimistic: According to Koyfin data, all 10 analysts covering ELVN stock rate it as a 'Buy', with a 12-month price target of $60.11, representing a potential upside of about 49% from the last closing price, reflecting strong market confidence in the company's future performance.
See More
Enliven Therapeutics Upsizes Public Offering to $400 Million
- Offering Size Increase: Enliven Therapeutics has increased its public offering size from an initially announced $250 million to $400 million, indicating strong market demand for its shares and providing the company with ample funding to advance its research and development efforts.
- Stock Pricing: The offering consists of 8.93 million shares of common stock priced at $37.50 per share, and additionally, pre-funded warrants to purchase up to 1.73 million shares at $37.499 per warrant, enhancing investor participation and potentially elevating the company's market position in the biopharmaceutical sector.
- Transaction Completion Timeline: The transaction is expected to close around June 15, 2026, reflecting the company's active engagement in the capital markets and confidence in future growth, while ensuring funding for subsequent clinical trials and product development.
- Underwriter Option: Underwriters have been granted a 30-day option to purchase up to an additional 1.6 million shares of common stock at the public offering price, providing the company with flexibility for further financing, which may play a crucial role in responding to future market demand changes.
See More
Enliven Therapeutics Completes Upsized Public Offering
- Upsized Offering: Enliven Therapeutics has priced its upsized public offering of 8,933,334 shares at $37.50 per share, expecting gross proceeds of approximately $400 million, which reflects strong market demand for its small molecule therapeutics and enhances the company's financial capacity to support R&D initiatives.
- Pre-Funded Warrant Option: Investors have the option to purchase up to 1,733,333 shares via pre-funded warrants at $37.499 each, a flexible financing approach that not only attracts more investors but also provides additional funding sources to address future market challenges.
- Strong Underwriter Lineup: The offering is managed by prominent financial institutions including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, which demonstrates market confidence in Enliven and adds significant credibility to the company's reputation in capital markets.
- Compliance and Transparency: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which enhances investor trust and aids the company in attracting more investors to support its long-term growth strategy.
See More
